Atrial Fibrillation, HIS Bundle Pacing
Conditions
Keywords
HIS Bundle Pacing, Atrial Fibrillation
Brief summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and estimates suggest its prevalence is increasing. Despite the advances in AF ablation strategies, the outcome of ablation procedures in persistent AF is still unsatisfactory. In addition, many patients are not candidates for ablation due to advanced age, comorbidities and previous failed ablation procedures. It is well known that there is no mortality benefit from rhythm versus rate control strategy in AF, therefore the increased number of AV node ablation and pacemaker insertion for patients with symptomatic AF with uncontrolled heart rate. Following AV node ablation, it is understandable that these patients will be paced 100% of the time where the value of physiological pacing will be at its most. The current standard practice is to pace the right ventricle for this cohort of patients unless they have severe LV systolic dysfunction when a biventricular pacing might be recommended. Previous data showed that RV pacing only can lead to deterioration of LV function, worsening of heart failure symptoms and increased mortality. HIS bundle pacing is a novel technique of pacing through placing the pacemaker lead on the junction box between the top and bottom chamber of the heart. This will allow the utilisation of the normal/intrinsic HIS Purkinjie (eclectic cables) to stimulate the ventricles. This can offer a physiological pacing modality and reduce pacing induced cardiomyopathy specially in pacing dependent pacing. The Ablate and Pace HIS Study proposes that the new method of HIS pacing is safe, effective and superior to the existing method of RV pacing in patients with atrial fibrillation who demonstrate signs of heart failure.
Detailed description
The Ablate and Pace HIS Study is a single-centre, prospective randomised single-blinded study, recruiting a sub-population of patients with AF who are deemed not fit for rhythm control strategy. These patients have been referred for a pacemaker implant and AVN node ablation as a symptomatic rate control option. The study aims to randomise a total of 100 participants into either the RV only pacing arm or the HBP arm. All patients will be implanted with a pacemaker device with one lead positioned in the right ventricle, and only in the HBP arm will an additional lead be positioned on the distal HIS bundle in order to obtain direct HIS-bundle capture. The RV lead will be only be used as a back-up option for the HBP arm if needed. Participants will undergo AVN ablation either at the same setting or 4-6 weeks later according to clinical indication and operator preference. A double-blinded design will then be employed to investigate the effect of HIS pacing. Endpoint measurements will be taken at Baseline, 4 weeks, 6 months and 12 months post randomisation. Treatment allocation will be blinded to the patients and endpoint assessor. All participants will be informed of their allocated treatment arm at the end of their 12 month follow up visit. Funding has been provided by Medtronic. The study Sponsor is University Hospitals of Leicester.
Interventions
PROCEDUREAblation and Pacemaker Implantation
All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
Sponsors
Medtronic
University Hospitals, Leicester
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18 or above * Symptomatic AF, New York Heart Association (NYHA) class II-IV * Willing to consent for the study * AF regardless type, deemed not suitable for rhythm control strategy that has been referred for AVN ablation with one of the following: 1. Impaired LV function, EF \<50 %. And or 2. Raised N-Terminal Pro B-type Natriuretic Peptide ( NT-ProBNP) \>365 ng/L
Exclusion criteria
* Patient who has already got a pacemaker in situ * Known severe LVSD when biventricular device is the thought to be the preferred pacing modality * Females in child bearing period * Lack of capacity to consent * Other serious medical condition with life expectancy of less than 1 year * Less than 18 years * Unwilling to consent for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with 20% improvement in 6 minutes-walk distance, AFEQT questionnaire score, and number of steps and distance walked per day assessed by a Fitbit smart watch | 12 months | 20% improvement in all 3 areas |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in NT-ProBNP level | 12 months | Change in NT-ProBNP level |
| Incidence of hospitalisation for heart failure, need for device upgrade to biventricular pacemaker or mortality | 12 months | Incidence of hospitalisation for heart failure, need for device upgrade to biventricular pacemaker or mortality |
| Improvement of LV function, LVESV assessed by echocardiogram | 12 months | Improvement of LV function, LVESV assessed by echocardiogram |
| Fluoroscopy time during the device insertion | During device insertion | Fluoroscopy time during the device insertion |
| Safety consideration: rate of infection, lead failure, displacement or the need for a repeat procedure | 12 months | Safety consideration: rate of infection, lead failure, displacement or the need for a repeat procedure |
| Pacing parameters | 12 months | RV threshold/HIS bundle lead will be checked, and this will be documented if it has changed. |
Countries
United Kingdom
Contacts
Primary ContactMokhtar Ibrahim, Dr
Outcome results
None listed